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ABSTRACT It is recognized that an ideal anti-cocaine treatment is to accelerate cocaine metabolism by producing biologically
inactive metabolites via a route similar to the primary cocaine-metabolizing pathway, i.e., butyrylcholinesterase (BChE)-cata-
lyzed hydrolysis of cocaine. BChE mutants with a higher catalytic activity against (-)-cocaine are highly desired for use as an
exogenous enzyme in humans. To develop a rational design for high-activity mutants, we carried out free-energy perturbation
(FEP) simulations on various mutations of the transition-state structures in addition to the corresponding free-enzyme structures
by using an extended FEP procedure. The FEP simulations on the mutations of both the free-enzyme and transition-state struc-
tures allowed us to calculate the mutation-caused shift of the free-energy change from the free enzyme (BChE) to the transition
state, and thus to theoretically predict the mutation-caused shift of the catalytic efﬁciency (kcat/KM). The computational predictions
are supported by the kinetic data obtained from the wet experiments, demonstrating that the FEP-based computational design
approach is promising for rational design of high-activity mutants of an enzyme. One of the BChE mutants designed and discov-
ered in this study has an ~1800-fold improved catalytic efﬁciency against (-)-cocaine compared to wild-type BChE. The high-
activity mutant may be therapeutically valuable.
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Cocaine is well known as the most reinforcing drug of abuse
(1–3). Currently, there is no anti-cocaine medication avail-
able. The disastrous medical and social consequences of
cocaine addiction have made the development of an anti-
cocaine medication a high priority (4,5). Unfortunately, the
classical pharmacodynamic approach, i.e., designing small
molecules to target the related transporters or receptors in
the central nervous system (CNS), has failed to yield a really
useful antagonist because of the difficulties inherent in block-
ing a blocker like cocaine (1–4,6). An alternative approach is
to interfere with the delivery of cocaine to its receptors or
accelerate its metabolism in the body (4). An ideal anti-
cocaine medication would be to accelerate cocaine metabo-
lism, producing biologically inactive metabolites via a route
similar to the primary cocaine-metabolizing pathway, i.e.,
cocaine hydrolysis catalyzed by plasma enzyme butyrylcholi-
nesterase (BChE) (4,7–11). However, wild-type BChE has
a low catalytic efficiency against naturally occurring
(-)-cocaine (12–16). Here we report a new computational
design and discovery of a high-activity mutant of human
BChE with an ~1800-fold improved catalytic efficiency
against (-)-cocaine, which could be used as an exogenous
enzyme in humans to prevent (-)-cocaine from reaching the
CNS. The results not only provide an encouraging new candi-
date for anti-cocaine medication, they also demonstrate that
the computational protocol used in this study is a promising
technique for rational enzyme redesign and drug discovery.
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0006-3495/09/03/1931/8 $2.00The primary pathway for cocaine metabolism in primates
is hydrolysis at the benzoyl ester or methyl ester group
(4,11). Benzoyl ester hydrolysis generates ecgonine methyl
ester (EME), whereas methyl ester hydrolysis yields benzoy-
lecgonine (BE). The major cocaine-metabolizing enzymes in
humans are butyrylcholinesterase (BChE), which catalyzes
benzoyl ester hydrolysis, and two liver carboxylesterases
(denoted hCE-1 and hCE-2), which catalyze hydrolysis at
the methyl ester and the benzoyl ester, respectively. Among
the three, BChE is the principal cocaine hydrolase in human
serum. Hydrolysis accounts for ~95% of cocaine metabolism
in humans. The remaining 5% is deactivated through oxida-
tion by the liver microsomal cytochrome P450 system,
producing norcocaine (4,17). EME appears to be the least
pharmacologically active of the cocaine metabolites and
may even cause vasodilation (4), whereas both BE and nor-
cocaine appear to cause vasoconstriction and lower the
seizure threshold, similarly to cocaine itself. Norcocaine is
hepatotoxic and a local anesthetic (4). Thus, hydrolysis of
cocaine at the benzoyl ester by BChE is the most suitable
metabolic pathway for amplification.
Generally speaking, for rational design of an enzyme
mutant with a higher catalytic activity for a given substrate,
one must design a mutation that can accelerate the rate-deter-
mining step of the entire catalytic reaction process while at the
same time the other steps are not slowed down by the muta-
tion. Reported computational modeling and experimental
data indicate that the formation of the prereactive BChE-
(-)-cocaine complex (ES) is the rate-determining step of
(-)-cocaine hydrolysis (Fig. 1) catalyzed by wild-type BChE
(12,13,18–20), whereas the rate-determining step of the
unnatural, biologically inactive (þ)-cocaine hydrolysis
doi: 10.1016/j.bpj.2008.11.051
FIGURE 1 Schematic representation of the first reaction
step of the chemical reaction process for (-)-cocaine hydro-
lysis catalyzed by BChE.
1932 Yang et al.catalyzed by the same enzyme is a chemical reaction process
consisting of four individual reaction steps (20,22). Based on
this mechanistic understanding, previous studies on the
rational design of BChE mutants focused on how to improve
the ES formation process, and several BChE mutants
(12,13,21) were found to have an ~9- to 34-fold improved
catalytic efficiency (kcat/KM) against (-)-cocaine. Recent find-
ings from computational modeling also suggest that the
formation of the prereactive BChE-(-)-cocaine complex
(ES) is hindered mainly by some amino acid residues in
wild-type BChE, but this hindrance can be removed by certain
mutations on those residues (13). Combined computational
and experimental data (12,19,22–25) reveal that the rate-
determining step of (-)-cocaine hydrolysis catalyzed by the
A328W/Y332A and A328W/Y332G mutants is the first
step in the chemical reaction process. Therefore, starting
from the A328W/Y332A or A328W/Y332G mutant, we
sought to further improve the catalytic efficiency of BChE
against (-)-cocaine by decreasing the energy barrier for the
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formation and other chemical reaction steps (22,24,26,27).
Rational design of BChE mutants starting from the A328W/
Y332A or A328W/Y332G mutant has led to the discovery
of several BChE mutants that have a considerably improved
catalytic efficiency against (-)-cocaine (18,22,24,26,27). As
confirmed by an independent group of researchers (28), our
previously reported high-activity mutant, A199S/S287G/
A328W/Y332G BChE (24), can indeed selectively block
cocaine toxicity and reinstatement of drug seeking in rats.
In the study presented here, the computational design of
new BChE mutants started from the A328W mutant instead
of the A328W/Y332A mutant. This is because the A328W
mutant has a higher catalytic efficiency than the A328W/
Y332A mutant against (-)-cocaine. The A328W mutant
(12) has a ~17.7-fold improved catalytic efficiency compared
to the wild-type, whereas the A328W/Y332A mutant has
a ~9.4-fold improved catalytic efficiency compared to the
wild-type. Our design protocol is based on examination of
the overall structure of the protein combined with an exten-
sion of the well-known free-energy perturbation (FEP)
approach (29,30) to predict the catalytic activity change
caused by a mutation on an enzyme. FEP can be performed
to evaluate the free-energy change caused by a small struc-
tural perturbation. In principle, it can only be used to simu-
late the change of a stable structure associated with a local
minimum on the potential energy surface (31–35). By using
our recently developed computational strategy that is appro-
priate for transition-state simulation (i.e., with the lengths of
transition bonds frozen) (22,24,26,27), we were also able to
simulate the mutations of the rate-determining transition-
state structure (in addition to the free-enzyme structure) by
using the FEP procedure. In contrast to previous FEP calcu-
lations concerning the effects of protein mutation on catalytic
efficiency of enzymes (36–38), FEP simulations on muta-
tions of both the free-enzyme and transition-state structures
allow us to calculate the mutation-caused shift of the free-
energy change from the free enzyme (BChE) to the rate-
determining transition state (i.e., TS1; see Fig. 1) (26), and
thus to theoretically evaluate/estimate the mutation-caused
shift of the catalytic efficiency (kcat/KM). The computational
predictions are consistent with the kinetic data obtained from
the wet experiments, demonstrating that the FEP-based
computational design approach is a promising technique
for the rational design of high-activity mutants of an enzyme.
MATERIALS AND METHODS
Computational studies
Before conducting FEP simulations on each mutation, we first performed
molecular-dynamics (MD) simulations on the unperturbed free-enzyme
and TS1 structures. The initial structures of both the free-enzyme and tran-
sition-state TS1 used in MD simulations were prepared based on our
previous MD simulations (24,25,27) on the structures of wild-type BChE
and its mutants, which were derived from the x-ray crystal structure (39)
deposited in the Protein Data Bank (40) with PDB code 1P0P. Each MD
simulation was carried out for at least 1 ns or longer until a stable MD trajec-
tory was obtained. The FEP simulations were carried out starting from the
MD-simulated structures of the unperturbed systems.
The schematic structure of the transition state TS1 is shown in Fig. 1.
Details of the determination of the TS1 structure were described previously
(26,27). Briefly, the key features of the TS1 structure involve the partially
formed and partially broken covalent bonds, i.e., transition bonds denoted
in this article formed within the catalytic triad (including Ser198, Glu325,
and His438) and the transition bond between the hydroxyl oxygen of
Ser198 side chain and a carbonyl carbon of the cocaine. The transition bonds
were restrained by defining the bond length parameters of new atom types of
specific atoms in the TS1 structure based on the geometry obtained from the
ab initio reaction coordinate calculations on the cocaine hydrolysis catalyzed
by wild-type BChE (20). The partial charges of the cocaine atoms in the TS1
structures were calculated by using the RESP protocol implemented in the
antechamber module of the AMBER 7 package (41) after electrostatic poten-
tial (ESP) calculations at the ab initio HF/6-31G* level using the
GAUSSIAN 03 program (42). The geometries used in the ESP calculations
were obtained from the previous ab initio reaction coordinate calculations
(20). The charges of the residue atoms of the TS1 structure were from the
standard AMBER force field used in the AMBER 7 package. The details
of the parameter development, the force-field parameters of the unusual
FEP Simulation and Redesign of BChEatom types in the TS1 structure, and the charges of the cocaine atoms are
provided in the Supporting Material (Fig. S1).
All of the MD simulations were performed with the use of the Sander
module of Amber7 package (41), using the same procedures as described
in our previous computational studies (24,27). For free-enzyme structures,
the þ1 charge of the enzyme was neutralized by adding one chloride coun-
terion. For the TS1 structure, the þ2 charge of the system was neutralized by
adding two chloride counterions. Both the free-enzyme and TS1 structures
were solvated in a rectangular box of TIP3P water molecule (43) with
a solute-wall distance of 10 A˚. The solvated systems were carefully equili-
brated and fully energy-minimized. We gradually heated these systems from
T¼ 10 K to T¼ 298.15 K in 40 ps before running the MD simulation at T¼
298.15 K for 1 ns or longer, making sure that we obtained a stable MD
trajectory for each of the simulated structures. The time step used for the
MD simulations was 2 fs. A periodic boundary condition was used in the
NPT ensemble at T ¼ 298.15 K with Berendsen temperature coupling and
P ¼ 1 atm with isotropic molecular-based scaling (44). The SHAKE algo-
rithm (45) was used to fix all covalent bonds containing hydrogen atoms.
The nonbonded pair list was updated every 25 steps. The particle mesh
Ewald (PME) method (46) was used to treat long-range electrostatic interac-
tions, and 10 A˚ was used as the nonbonded cutoff.
The outcomes of the FEP simulations on the mutations of both the free-
energy and TS1 structures can be used to predict the mutation-caused
changes in the catalytic efficiency for BChE-catalyzed hydrolysis of
(-)-cocaine. Depicted in Fig. 2 are the free-energy changes associated with
two reaction systems: one is the (-)-cocaine hydrolysis catalyzed by
a BChE mutant (or the wild-type), denoted by enzyme 1 or E(1); the other
is the (-)-cocaine hydrolysis catalyzed by another BChE mutant, denoted
by enzyme 2 or E(2). As shown in Fig. 2, the catalytic efficiency, i.e.,
kcat(i)/KM(i), for the (-)-cocaine hydrolysis catalyzed by enzyme E(i) is deter-
mined by the Gibbs free-energy change DG(i) of the reaction system from
E(i) plus substrate S, i.e., (-)-cocaine, to the corresponding rate-determining
transition state TS1(i). DG(i) is the sum of the enzyme-substrate binding free
energy DGES(i) and the activation free energy DGav(i):
DGðiÞ ¼ DGESðiÞ þ DGavðiÞ; i ¼ 1 and 2: (1)
When a mutation on an amino acid residue can change the enzyme from E(1)
to E(2), we want to know the corresponding free-energy change from DG(1)
to DG(2) for the computational design of the high-activity mutants of the
enzyme. There are two possible paths to determine the free-energy change
DDG(1/2) h DG(2)  DG(1). One path is to directly calculate DGES(i)
and DGav(i) associated with E(1) and E(2), which is very computationally
demanding in terms of the level of theory. For an alternative path, the rela-
tively less-demanding FEP simulations allow us to estimate DDG(1/2) by
determining the free-energy changes DGE and DGTS1 from E(1) to E(2):
DDGð1/2Þ ¼ DGTSI  DGE; (2)
FIGURE 2 The relationship between different free-energy changes for the
reactions catalyzed by two enzymes. E(i) is the free enzyme, ES(i) represents
the enzyme-substrate complex, and TS1(i) refers to the transition state.
DG(i) is the sum of the enzyme-substrate binding free energy DGES(i) and
the activation free energy DGav(i) (i ¼ 1, 2).
Biophysical Journal 96(5) 1931–1938
1933
where DGE and DGTS1 are the free-energy changes from E(1) to E(2) for the
free enzyme and TS1, respectively. DGE and DGTS1 were estimated by
performing the FEP simulations in the study presented here. By using the
calculated DDG(1/2), the ratio of the catalytic efficiency associated with
E(2) to that associated with E(1) can be evaluated via:
DDGð1/2Þ ¼ RTlnkcatð2Þ=KMð2Þ
kcatð1Þ=KMð1Þ: (3)
Equation 3 can also be used to derive the experimental DDG(1/2) value
from the experimental ratio of the catalytic efficiency associated with E(2)
to that associated with E(1).
We tested the above FEP-based computational approach for various muta-
tions, including those associated with the following enzyme changes:
A328W/A328W=A199S (4)
A328W=A199S/A328W=A199S=F227A (5)
A328W=A199S=F227A/A328W=A199S=F227A=E441D
(6)
A328W=A199S=F227A=E441D/A328W=
A199S=F227A=E441D=S287A ð7Þ
A328W=A199S=F227A=E441D=S287A/A328W=
A199S=F227A=E441D=S287G: ð8Þ
The mutation A199S associated with the BChE mutant change from A328W
to A328W/A199S increases the size of the side chain, whereas the other
mutations all decrease the size of the side chain. For technical reasons, it
is always more convenient to perform an FEP simulation on the change
from a larger side chain to a smaller side chain. So, for A328W /
A328W/A199S, we actually carried out the FEP simulation from A328W/
A199S to A328W and used the following energy relationship:
DDGð1/2Þ ¼ DDGð2/1Þ: (9)
For the diminishing atoms during the perturbation simulation from a larger
side chain to a smaller side chain, the dummy atoms were added to the per-
turbed residue to keep the number of atoms constant. Thus, some normal
atoms in the starting residue were gradually mutated to the dummy atoms
in the perturbed residue. For the dummy atoms, a new atom type, DH,
was given to the diminished hydrogen, and atom type DC was given to
the diminished carbon atom in the mutations F227A and E441D. The
charges and the nonbond parameters of the dummy atoms were set to zero
so that they would not have electrostatic or van der Waals interactions
with other atoms. At the same time, all of the bond and angle parameters
involving the dummy atoms were the same as their counterparts in the initial
structure to keep the structural skeletons unchanged. The residue structures
before and after perturbations, and the force-field parameters of the dummy
atoms are provided in the Supporting Material. The default choice (INTPRT
¼ 0) was used to make sure that the bonded interactions of the dummy atoms
would be excluded from the final calculation on the total energy of the per-
turbed system. The FEP simulations (with a time step of 1 fs) were carried
out by using the ‘‘fixed width window growth’’ method implemented in the
Gibbs module of AMBER7 (41).
To enlarge the phase space searched by the FEP calculation, for each
perturbation, 10 different conformations were extracted from the stable
MD trajectory with an interval of 100 ps (one snapshot per 100 ps). The
equally distributed 10 snapshots of the simulated structure within the stable
MD trajectory were used as the initial structures of the perturbation simula-
tions. The finally calculatedDGTS1 or DGE value is the average of the DGTS1
or DGE values associated with the initial structures. Each initial structure
Biophysical Journal 96(5) 1931–1938
1934was first energy-minimized for 1000 cycles followed by 40 ps MD simula-
tion for the heating and equilibration to obtain a better starting structure for
the FEP calculation. For FEP calculations on all mutations except two, we
used 51 windows (Dl ¼ 0.02) with 1250 steps of equilibration and
1250 steps for data collection, with both forward and backward directions
in each FEP calculation. The exceptions were the enzyme changes
A328W/A199S/A328W/A199S/F227A and A328W/A199S/F227A/
A328W/A199S/F227A/E441D. For the mutation F227A or E441D in these
two enzyme changes, 101 windows (Dl ¼ 0.01) were used to obtain a more
stable FEP performance. Thus, for the FEP simulation on each mutation, we
performed the MD simulations for a total of 2500  51  10 ¼ 1,275,000
(or 2500  101  10 ¼ 2,525,000) steps or 1.275 (or 2.525) ns.
Experimental studies
Cloned pfu DNA polymerase and Dpn I endonuclease were obtained from
Stratagene (La Jolla, CA). [3H](-)-cocaine (50 Ci/mmol) was purchased
from PerkinElmer Life Sciences (Boston, MA). The expression plasmid
pRc/CMV was a gift from Dr. O. Lockridge, University of Nebraska
Medical Center (Omaha, NE). All oligonucleotides were synthesized by
Integrated DNA Technologies (Coralville, IA). QIAprep spin plasmid mini-
prep, Qiagen plasmid purification, and QIAquick PCR purification kits were
obtained from Qiagen (Santa Clarita, CA). Human embryonic kidney 293T/
17 cells were obtained from ATCC (Manassas, VA). Dulbecco’s modified
Eagle’s medium (DMEM) was purchased from Fisher Scientific (Fairlawn,
NJ). 3, 30, 5, 50-Tetramethylbenzidine (TMB) was obtained from Sigma
(St. Louis, MO). Anti-butyrylcholinesterase (mouse monoclonal antibody,
product No. HAH002-01) was purchased from AntibodyShop (Gentofte,
Denmark), and goat anti-mouse IgG HRP conjugate was obtained from
Zymed (San Francisco, CA).
Site-directed mutagenesis of human BChE cDNA was performed by means
of the QuikChange method (47). Mutations were generated from wild-type
human BChE in a pRc/CMV expression plasmid (48). Using plasmid DNA
as the template and primers with specific basepair alterations, mutations
were made by polymerase chain reaction (PCR) with Pfu DNA polymerase,
for replication fidelity. The PCR product was treated withDpn I endonuclease
to digest the parental DNA template. Modified plasmid DNA was transformed
into Escherichia coli, amplified, and purified. The DNA sequences of the
mutants were confirmed by DNA sequencing. BChE mutants were expressed
in human embryonic kidney cell line 293T/17. Cells were grown to 80% to
90% confluence in six-well dishes and then transfected by Lipofectamine
2000 complexes of 4 mg plasmid DNA per each well. Cells were incubated
at 37C in a CO2 incubator for 24 h; they were then moved to a 60-mm culture
vessel and cultured for 4 more days. The culture medium (10% fetal bovine
serum in DMEM) was harvested for a BChE activity assay. To measure
(-)-cocaine and benzoic acid, the product of (-)-cocaine hydrolysis catalyzed
by BChE, we used sensitive radiometric assays based on toluene extraction of
[3H]-(-)-cocaine labeled on its benzene ring (49). In brief, to initiate the enzy-
matic reaction, 100 nCi of [3H]-(-)-cocaine was mixed with 100 mL of culture
medium. The enzymatic reactions proceeded at room temperature (25C)
with varying concentrations of (-)-cocaine. The reactions were stopped by
adding 300 mL of 0.02 M HCl, which neutralized the liberated benzoic acid
while ensuring a positive charge on the residual (-)-cocaine. [3H]benzoic
acid was extracted by 1 mL of toluene and measured by scintillation counting.
Finally, the measured (-)-cocaine concentration-dependent radiometric data
were analyzed by using the standard Michaelis-Menten kinetics so that the
catalytic parameters (kcat and KM) were determined along with the use of an
enzyme-linked immunosorbent assay (ELISA) (50) as described below.
The ELISA buffers used in this study were the same as those described in
the literature (50). The coating buffer was 0.1 M sodium carbonate/bicar-
bonate buffer, pH 9.5. The diluent buffer (EIA buffer) was potassium phos-
phate monobasic/potassium phosphate dibasic buffer, pH 7.5, containing
0.9% sodium chloride and 0.1% bovine serum albumin. The washing buffer
(PBS-T) was 0.01 M potassium phosphate monobasic/potassium phosphate
dibasic buffer, pH 7.5, containing 0.05% (v/v) Tween-20. All of the assays
were performed in triplicate. Each well of an ELISA microtiter plate was
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filled with 100 mL of a mixture buffer consisting of 20 mL culture medium
and 80 mL coating buffer. The plate was covered and incubated overnight at
4C to allow the antigen to bind to the plate. The solutions were then
removed and the wells were washed four times with PBS-T. The washed
wells were filled with 200 mL diluent buffer and shaken for 1.5 h at room
temperature (25C). After the wells were washed four times with PBS-T,
they were filled with 100 mL antibody (1:8,000) and incubated for 1.5 h, fol-
lowed by four more washings. Then the wells were filled with 100 mL goat
anti-mouse IgG HRP conjugate complex diluted to a final 1:3000 dilution,
incubated at room temperature for 1.5 h, and washed four more times.
The enzyme reactions were started by addition of 100 mL substrate
(TMB) solution (50). The reactions were stopped after 15 min by the addi-
tion of 100 mL of 2 M sulfuric acid, and the absorbance was read at 460 nm
using a Bio-Rad ELISA plate reader.
RESULTS AND DISCUSSION
To predict the DDG(1/2) values and the catalytic effi-
ciency changes for the mutations A199S, F227A, E441D,
S287A, and A287G associated with enzyme changes (4)–
(8) or the change from the A328W mutant to the A328W/
A199S/F227A/E441D/S287G mutant of BChE, we per-
formed MD simulations on both the free enzyme and TS1
structures of mutants A328W/A199S, A328W/A199S/
F227A, A328W/A199S/F227A/E441D, and A328W/
A199S/F227A/E441D/S287A. Stable MD trajectories with
the simulation time of 1 ns or longer were obtained for these
structures. Depicted in Fig. 3 are the MD-simulated TS1
structures of A328W and A328W/A199S/F227A/E441D/
S287G mutants of BChE. Indicated in the figure are the loca-
tions of mutated residues 199, 227, 287, and 441 relative to
cocaine, along with other key residues forming the catalytic
triad (residues 198, 325, and 438) and oxyanion hole (resi-
dues 116, 117, and 328) in the active site. The yellow dashed
lines represent the hydrogen bonds between the oxyanion
hole and the carbonyl oxygen of benzoyl ester of cocaine,
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figures about the time-dependence of some key internuclear
distances and the root mean-square deviation (RMSD) of the
simulated positions of the protein backbone atoms from
those in the initial structure in the MD-simulated TS1 struc-
ture are provided in the Supporting Material. The equally
distributed 10 snapshots of the MD-simulated free-enzyme
or TS1 structure extracted from the stable trajectory with
a time interval of 100 ps were used as the starting structures
to perform the FEP simulations.
Important energetic results of the FEP simulations for
enzyme changes (4)–(8) are summarized in Table 1. More
detailed energetic results obtained from the FEP simulations
are provided in the Supporting Material, including the incre-
mental changes of theDGTS1 andDGE values associated with
each mutation as a function of l parameter (window number),
showing the smooth changes of the calculated DGTS1 and
DGE values. In Table 1, the values of the root mean-square
fluctuation (RMSF) among the individual energy changes
associated with different initial structures are given in paren-
theses. As shown in Table 1, the absolute values ofDGTS1 and
DGE range from 5.0 to 11.1 kcal/mol, whereas the RMSF
values range from 0.3 to 0.8 kcal/mol. The RMSF values of
our FEP calculations are comparable to previously reported
fluctuation values associated with different independent
FEP runs on the same system in other computational studies
(36,51,52). It should be pointed out that the RMSF values
do not necessarily reflect the computational errors of the
FEP calculations. In general, the greater the number of start-
ing structures used in FEP simulations, the more reliable are
the average DGTS1 and DGE values obtained. Our previous
computational studies (27) demonstrated that the average
energetic results calculated by using five different starting
structures are close to the corresponding average results
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FIGURE 3 (A) The MD-simulated TS1 structure associated with the A328W mutant. The dashed lines in yellow indicate the hydrogen bonds between
(-)-cocaine and the oxyanion hole of the mutant. The simulated average distances are given for the hydrogen bonds. The dashed lines in white refer to the
transition bonds. (B) The MD-simulated TS1 structure associated with the A328W/A199S/F227A/E441D/S287G mutant. (C) Superimposition of the two
TS1 structures associated with the A328W mutant (yellow) and A328W/A199S/F227A/E441D/S287G mutant (pink).
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TABLE 1 FEP-calculated free-energy changes (in kcal/mol) in comparison with experimental kinetic data for (-)-cocaine hydrolysis
catalyzed by BChE mutants
Mutation
Calc* Expt.y
DGE DGTS1 DDG(1/2) DDG(1/2)
A328W/A328W/A199S 9.0 (0.6) 11.1(0.8) 2.1 1.04
A328W/A199S/A328W/A199S/F227A 5.9(0.5) 5.0(0.4) 0.9 0.74
A328W/A199S/F227A/A328W/A199S/
F227A/E441D
7.6(0.3) 7.5(0.6) 0.1 N.D.x
A328W/A199S/F227A/E441D/A328W/
A199S/F227A/E441D/S287A
8.2(0.4) 7.9(0.5) 0.3 N.D.x
A328W/A199S/F227A/E441D/S287A/
A328W/A199S/F227A/E441D/ S287G
5.6(0.4) 6.5(0.6) 0.9 N.D.x
A328W/A199S/F227A/A328W/A199S/
F227A/E441D/ S287Gz
10.2 8.9 1.3 0.96
Experimental kinetic parameters and total free-energy change from A328W
Mutant kcat (min
1) KM (mM) kcat/KM (min
1M1) Relative kcat/KM** DDG
yy
Wild-type BChE{ 4.1 4.5 9.11  105 1 N.A.
A328W{ 50 3.1 1.61  107 17.7 0
A199S/A328Wk 173 1.86 9.28  107 102 1.04
A199S/A328W/F227Ak 472 1.46 3.23  108 355 1.78
A328W/A199S/F227A/E441D/S287Gk 1326 0.81 1.64  109 1800 2.74
N.A., Not applicable.
*DGE and DGTS1 are the mutation-caused free-energy changes for the free-enzyme and transition states, respectively. The number in parentheses after the
DGE or DGTS1 value refers to the RMSF of the DGE or DGTS1 values calculated starting from the 10 initial structures.
yThe experimental DDG(1/2) values were derived from the experimental kcat/KM values.
zThe theoretical results were derived from the FEP results obtained for the enzyme changes A328W/A199S/F227A/ A328W/A199S/F227A/E441D/
A328W/A199S/F227A/E441D/S287A/ A328W/A199S/F227A/E441D/ S287G.
xThe experimental data were not determined.
{Experimental data from Sun et al. (12).
kThe kinetic parameters determined in this study.
**The relative kcat/KM refers to the ratio of the catalytic efficiency of the BChE mutant to that of the wild-type against (-)-cocaine.
yyThe cumulative DDG derived from experimental kinetic data from the A328W mutant to the mutant under consideration.
1936 Yang et al.calculated by using 10 different starting structures, suggesting
that the use of five or 10 different starting structures for FEP
calculations on BChE-cocaine systems is adequate.
As shown in Table 1, the DDG(1/2) values associated
with enzyme changes (4)–(8) were all predicted to have
a minus sign, which means that the mutations associated
with enzyme changes (4)–(8) can all increase the catalytic effi-
ciency of the enzyme against (-)-cocaine. The energetic data
summarized in Table 1 can be understood by examining the
simulated structures. Residue 199 belongs to the oxyanion
hole in the active site that provides a hydrogen-bond-donor
environment for the enzyme to form hydrogen bonds with
the carbonyl oxygen of benzoyl ester of cocaine during the
enzymatic hydrolysis. The DDG(A328W/A328W/A199S)
value of 2.1 kcal/mol is mainly attributed to the formation
of the additional hydrogen bond between the hydroxyl group
of the S199 side chain and the carbonyl oxygen of cocaine in
the mutated TS1 structure, as shown in Fig. 3, A and B.
Residue F227 is located on the end of the turn between two
loops that form the boundary of the active site pocket of
the enzyme. The DDG(A328W/A199S/A328W/A199S/
F227A) value of 0.9 kcal/mol is due to the indirect effects
of the F227A mutation on the active site cavity. After the
F227A mutation (from a larger residue to a smaller one), the
Biophysical Journal 96(5) 1931–1938active site cavity becomes slightly larger so that it can better
accommodate (-)-cocaine, which is larger in size than the
substrate butyrylcholine. Residue E441 is two residues
away from the boundary of the active site pocket. When
E441 was mutated to a smaller residue, i.e., from Glu to
Asp, the residue slightly shifted further away from the active
site pocket such that the overall size of the active site pocket
slightly increased during the simulation. Consistent with
the effects on the steric interactions, the mutation E441D cor-
responding to the change A328W/A199S/F227A/A328W/
A199S/F227A/E441D slightly decreased the free-energy
change by 0.1 kcal/mol. For the DDG(A328W/A199S/
F227A/E441D/A328W/A199S/F227A/E441D/S287A) and
DDG(A328W/A199S/F227A/E441D/S287A/A328W/A199S/
F227A/E441D/S287G values (0.3 and0.9 kcal/mol) with
a minus sign, residue 287 is close to the benzene ring of
(-)-cocaine, and the S287G mutation makes more room and
a hydrophobic environment to better accommodate the
benzene ring of (-)-cocaine. The slightly enlarged active site
cavity of the TS1 structure associated with mutant A328W/
A199S/F227A/E441D/S287G relative to mutant A328W
can be seen in a figure provided in the Supporting Material.
The computational results predict that the A328W/A199S/
F227A/E441D/S287G mutant is expected to have the highest
catalytic efficiency within all of the mutants examined in this
study. The computational predictions based on the FEP
simulations are supported by our experimental kinetic
parameters for the mutants. The A328W BChE is known
to have a ~17.7-fold improved catalytic efficiency against
(-)-cocaine (12). In the study presented here, we produced
the A328W/A199S/F227A/E441D/S287G mutant of human
BChE, for the first time to our knowledge, by performing
site-directed mutagenesis, protein expression, and activity
assays. For comparison, we also produced and tested the
A328W/A199S and A328W/A199S/F227A mutants, along
with wild-type BChE, by using the same experimental
protocol.
The experimental kinetic parameters are summarized in
Table 1 for comparison with the calculated free-energy
changes. As one can see in Table 1, kcat ¼ 173 min1 and
KM ¼ 1.86 mM for A328W/A199S BChE, kcat ¼ 472 min1
and KM ¼ 1.46 mM for A328W/A199S/F227A BChE, and
kcat ¼ 1326 min1 and KM ¼ 0.81 mM for A328W/A199S/
F227A/E441D/S287G BChE against (-)-cocaine. Thus,
compared to wild-type BChE against (-)-cocaine (kcat ¼
4.1 min1 and KM ¼ 4.5 mM) (12), A328W/A199S BChE
has a ~102-fold improved catalytic efficiency (kcat/KM),
A199S/A328W/F227A BChE has a ~355-fold improved cata-
lytic efficiency, and A328W/A199S/F227A/E441D/S287G
BChE has a ~1800-fold improved catalytic efficiency. The
experimental kinetic data are all qualitatively consistent with
the computational predictions based on the FEP simulations.
CONCLUSIONS
In summary, this integrated computational-experimental study
resulted in a new high-activity mutant of human BChE with an
~1800-fold improved catalytic efficiency against (-)-cocaine.
Using the designed A328W/A199S/F227A/E441D/S287G
BChE as an exogenous enzyme in human, when the concentra-
tion of this mutant is kept the same as that of wild-type BChE
in plasma, the half-life of (-)-cocaine in plasma should be
reduced from ~4590 min (in the presence of wild-type
BChE) to only ~1.5–3.0 s (in the presence of A328W/
A199S/F227A/E441D/S287G BChE). The computational
and experimental data also demonstrate that the computational
design protocol based on the FEP simulations of transition
states is promising for rational design of high-activity mutants
of an enzyme. The general computational design protocol may
be used to study the effects of a mutation on the activation free
energy for any enzymatic reaction, although it is necessary to
further test the reliability of the protocol for other enzyme
systems. Experimental studies on the mechanisms of enzy-
matic reactions usually include site-directed mutagenesis on
some key amino acid residues to determine the effects of the
mutations on the catalytic activity. FEP-based transition-state
simulations may provide a convenient computational
approach to reliably evaluate such effects by directly
comparing them with experimental data.
FEP Simulation and Redesign of BChESUPPORTING MATERIAL
Fourteen figures and parameters are available at http://www.biophysj.org/
biophysj/supplemental/S0006-3495(09)00225-2.
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